Pfizer Reports Phase 3 Data for Lebrikizumab in Sickle cell disease

Pfizer today announced Phase 3 results for lebrikizumab in patients with sickle cell disease. The study demonstrated that lebrikizumab reduces exacerbation rates compared to standard of care or placebo. These results provide important insights into the treatment of sickle cell disease and support the continued development of lebrikizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.